loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Etigilimab

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Etigilimab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mereo BioPharma Reports Clinical & Interim Biomarker Analysis at ESMO 2022
    Mereo BioPharma Reports Clinical & Interim Biomarker Analysis at ESMO 2022

    12 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/12/2513977/0/en/Mereo-BioPharma-Reports-Clinical-Update-and-Interim-Biomarker-Analysis-Presented-at-ESMO-2022-from-ACTIVATE-Phase-1b-2-Open-Label-Study-of-Etigilimab-Anti-TIGIT-Antibody-MPH-313-pl.html

    GLOBENEWSWIRE
    12 Sep 2022
    Share Share
    Mereo BioPharma To Present Data for PIb/II Study of Etigilimab + Nivolumab
    Mereo BioPharma To Present Data for PIb/II Study of Etigilimab + Nivolumab

    02 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/02/2455163/0/en/Mereo-BioPharma-To-Present-Data-Update-for-the-Phase-1b-2-Study-ACTIVATE-of-Etigilimab-and-Nivolumab-at-2022-ASCO-Annual-Meeting-Mereo-Also-Updates-Capital-Allocation-and-Portfolio.html

    GLOBENEWSWIRE
    02 Jun 2022
    Share Share
    Mereo BioPharma to Present Updated Data From PI/II Study of Etigilimab
    Mereo BioPharma to Present Updated Data From PI/II Study of Etigilimab

    26 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/26/2451674/0/en/Mereo-BioPharma-Announces-the-Presentation-of-Updated-Data-From-a-Phase-1b-2-Study-of-Etigilimab-as-a-Poster-at-the-2022-American-Society-of-Clinical-Oncology-Annual-Meeting.html

    GLOBENEWSWIRE
    26 May 2022
    Share Share
    Mereo Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab
    Mereo Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab

    19 Oct 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/10/19/2110294/0/en/Mereo-BioPharma-Announces-FDA-Clearance-to-Proceed-into-a-Phase-1b-2-study-for-Etigilimab-Anti-TIGIT.html

    GLOBENEWSWIRE
    19 Oct 2020
    Share Share
    Celgene says no to Mereo’s cancer drug etigilimab
    Celgene says no to Mereo’s cancer drug etigilimab

    27 Jun 2019

    // Phil Taylor PMLIVE

    http://www.pmlive.com/pharma_news/celgene_says_no_to_mereos_cancer_drug_etigilimab_1291381

    Phil Taylor PMLIVE
    27 Jun 2019
    Share Share
    Celgene says no to Mereo’s cancer drug etigilimab
    Celgene says no to Mereo’s cancer drug etigilimab

    22 Jun 2019

    // Phil Taylor PM LIVE

    http://www.pmlive.com/pharma_news/celgene_says_no_to_mereos_cancer_drug_etigilimab_1291381

    Phil Taylor PM LIVE
    22 Jun 2019
    Share Share